Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec 1;16(1):70.
doi: 10.1186/s12902-016-0149-z.

Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study

Hiroshi Sakura  1 , Naotake Hashimoto  2 , Kazuo Sasamoto  3 , Hiroshi Ohashi  4 , Sumiko Hasumi  5 , Noriko Ujihara  6 , Tadasu Kasahara  7 , Osamu Tomonaga  8 , Hideo Nunome  9 , Masashi Honda  10 , Yasuhiko Iwamoto  11 ; JAMP Study Investigators
Collaborators, Affiliations

Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study

Hiroshi Sakura et al. BMC Endocr Disord. .

Abstract

Background: To investigate the ameliorating effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood glucose control in patients with type 2 diabetes mellitus who were previously untreated with or who have a poor responsive to existing antidiabetic drugs.

Methods: Sitagliptin (50 mg/day) was added on to the pre-existing therapy for type 2 diabetes and changes in the glycated hemoglobin (HbA1c) level after 3 months of treatment were compared with the baseline and performed exploratory analysis.

Results: HbA1c levels were significantly decreased after 1 month of treatment compared to baseline, with a mean change in HbA1c level from baseline of -0.73% (range, -0.80 to -0.67) in the entire study population at 3 months. Patients who received a medium dose of glimepiride showed the least improvement in HbA1c levels. The percentage of patients who achieved an HbA1c level of <7.0% significantly increased after 1 month of treatment, reaching 53.1% at 3 months. The percentage of patients who achieved a fasting blood glucose level of <130 mg/dL significantly increased after 1 month of treatment, reaching 50.9% at 3 months.

Conclusions: Sitagliptin improved the HbA1c level and rate of achieving the target control levels in patients with type 2 diabetes mellitus who were previously untreated with, or poorly responsive to, existing antidiabetic drugs. Thus, sitagliptin is expected to be useful in this patient group. However, the additional administration of sitagliptin in patients treated with medium-dose glimepiride only slightly improved blood glucose control when corrected for baseline HbA1c level.

Keywords: DPP-4 inhibitor; Diabetes mellitus; Glimepiride; HbA1c; Sitagliptin.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study design. *1 Criteria for inadequate blood glucose control: HbA1c level ≥6.9% (52 mmol/mol) or fasting blood glucose level ≥130 mg/dL. *2 Specific investigational tests (optional): GA, 1.5AG, C-peptide, proinsulin-to-insulin ratio
Fig. 2
Fig. 2
Patient enrollment flow diagram
Fig. 3
Fig. 3
∆HbA1c level according to concomitant drug type (3 months)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Results of “National Health and Nutrition Survey” . Ministry of Health, Labour and Welfare. 2012.
    1. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–43. doi: 10.1056/NEJMoa066224. - DOI - PubMed
    1. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632–7. doi: 10.2337/dc06-0703. - DOI - PubMed
    1. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2638–43. doi: 10.2337/dc06-0706. - DOI - PubMed
    1. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:1556–68. doi: 10.1016/j.clinthera.2006.10.007. - DOI - PubMed